{"url_path":"/sec/vbio/8-k/2026-07-14/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","accession_number":"0001683168-26-005497","cik":"0001787740","ticker":"VBIO","issuer_name":"Valion Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","primary_entity_key":"0001787740","primary_entity_name":"Valion Bio, Inc."},"word_count":312,"has_tables":true,"body_markdown":"Tivic Health Systems, Inc. Form 8-K\n\nfalse\n0001787740\n\n0001787740\n\n2026-07-14\n2026-07-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION****WASHINGTON, D.C. 20549**\n\n** **\n\n \n\n**FORM 8-K**\n\n \n\n** **\n\n**CURRENT REPORT**\n\n** **\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\n** **\n\n**Date of Report (Date\nof earliest event reported): July 14,\n2026**\n\n \n\n \n\n \n\n**Valion\nBio, Inc.**\n\n**(Exact name of Registrant as Specified in Its\nCharter)**\n\n** **\n\n \n\n \n\nDelaware\n001-41052\n81-4016391\n\n(State or Other Jurisdiction\n(Commission File Number)\n(IRS Employer\n\nof Incorporation)\n \nIdentification No.)\n\n \n \n \n\n**1305 E. Houston Street,**\n\n**Building 1, Suite 311**\n\n \n \n\nSan Antonio, Texas\n \n78205\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\n**Registrant’s Telephone Number, Including Area Code: 888 276-6888**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered pursuant to Section 12(b)\nof the Act:**\n\n \n\n**Title of each class**\n \n**Trading\nSymbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n \nVBIO\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}